title: The role of hormonal therapy in gynecological cancers-current status and future directions.
abstract: Many gynecological cancers, including epithelial and stromal ovarian cancers; endometrial carcinomas; and some gynecological sarcomas, in particular endometrial stromal sarcomas, express estrogen and/ or progesterone receptors. Hormonal therapy, typically progestogens or tamoxifen, is commonly prescribed to patients with potentially hormone-sensitive recurrent or metastatic gynecological cancers with very variable response rates and clinical benefit reported. Aromatase inhibitors are now widely used to treat postmenopausal women with hormone receptor-positive breast cancers as they have greater activity than tamoxifen and are generally better tolerated. The role of aromatase inhibitors in gynecological cancers is uncertain and has not been well studied, although they do appear to be active. The current evidence to support the use of hormonal therapies including aromatase inhibitors in gynecological cancers is reviewed, and the gaps in our knowledge highlighted.
authors: NHMRC Clinical Trials Centre, University of Sydney, Australia.
authors: Katrin M
authors: KM
authors: Sjoquist
authors: Julie
authors: J
authors: Martyn
authors: Richard J
authors: RJ
authors: Edmondson
authors: Michael L
authors: ML
authors: Friedlander
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006106:Granulosa Cell Tumor / Q000188:drug therapy; D020249:Hormone Replacement Therapy; D006801:Humans; D012509:Sarcoma / Q000188:drug therapy*
chemical_list: D047072:Aromatase Inhibitors